恩考芬尼联合比美替尼治疗 BRAF V600E 突变型转移性 NSCLC：PHAROS 研究的临床意义。
Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.
机构信息
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA 30322, USA.
出版信息
Future Oncol. 2024;20(33):2503-2508. doi: 10.1080/14796694.2024.2391270. Epub 2024 Sep 3.
Drs. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. The podcast provides an overview of the data from the recent Pfizer-sponsored phase 2 PHAROS (NCT03915951) study, which were the basis for the recent US Food and Drug Administration approval of encorafenib plus binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer.
拉马林加姆博士和卡莱尔博士讨论了 BRAF V600E 突变型转移性非小细胞肺癌的发生率和病理生理学，以及当前的治疗选择。该播客概述了辉瑞公司赞助的最近的 PHAROS（NCT03915951）的研究数据，这些数据是最近美国食品和药物管理局批准 encorafenib 加 binimetinib 用于治疗 BRAF V600E 突变型转移性非小细胞肺癌的基础。
Zotero 插件